STOCKHOLM, Sweden--(BUSINESS WIRE)--Biopharma company Biovitrum (STO:BVT), listed on the Stockholm Stock Exchange since September 15, 2006, has entered an agreement with the Uppsala-based biotech company Resistentia Pharmaceuticals AB for process development and manufacturing of the biopharmaceutical substance RES 08 intended for use in clinical phase III trials of Resistentia’s new protein-based drug candidate for the treatment of allergy.
